---
title: "ddddds"
categories:
  - Alzheimer's Disease
tags:
  - dementia
  - treatment pathways
  - drug-drug interactions
toc: true
---
 
## Paper Reading

### Treatment Pathways
   â€” defined here as the ordered sequence of medications that a patient is prescribed.
   {: .small}

> <font color='red'>Paper:</font> Hripcsak, George, et al. "[Characterizing treatment pathways at scale using the OHDSI network](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941483/pdf/pnas.201510502.pdf)." Proceedings of the National Academy of Sciences 113.27 (2016): 7329-7336.
{: .small}

* Our aim was to reveal patterns and variation in treatment among data sources and diseases.
* The pathways revealed that the world is moving toward more consistent therapy over time across diseases and across locations, but significant heterogeneity remains among sources, pointing to challenges in generalizing clinical trial results. Diabetes favored a single first-line medication, metformin, to a much greater extent than hypertension or depression. About 10% of diabetes and depression patients and almost 25% of hypertension patients followed a treatment pathway that was unique within the cohort.
* Aside from factors such as sample size and underlying population (academic medical center versus general population), electronic health records data and administrative claims data revealed similar results. 
{: .small}

### Drug Repurposing for AD

> <font color='red'>Paper:</font> Fang, Jiansong, et al. "[Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer's Disease](https://www.medrxiv.org/content/10.1101/2020.01.15.20017160v1.full.pdf)." medRxiv (2020).

### Drug-drug Interactions

> <font color='red'>Paper:</font> Bogetti-Salazar, Michele, et al. "[Severe potential drug-drug interactions in older adults with dementia and associated factors](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763155/pdf/cln-71-01-017.pdf)." Clinics 71.1 (2016): 17-21.
{: .small}

* The main severe potential drug-drug interactions (DDIs) were caused by the combinations [citalopram](https://www.drugs.com/citalopram.html)/[antiplatelet](https://www.drugs.com/drug-class/antiplatelet-agents.html) (11.6%), [clopidogrel](https://www.drugs.com/mtm/clopidogrel.html)/[omeprazole](https://www.drugs.com/omeprazole.html) (6.1%), and clopidogrel/ aspirin (5.5%). 
* Antidepressants, antiplatelets, anti-psychotics and omeprazole were the drugs most commonly involved in severe potential drug-drug interactions. 
* Despite their frequent use, anti-dementia drugs were not involved in these interactions. 
* The number and type of medications taken, dementia severity and depression in patients in addition to caregiver burden should be considered to avoid possible drug interactions in this population.
* <font color='green'>Top ten severe potential DDIs (severe and contraindicated).</font>
{: .small}


